David Castaneda | Investor Relations |
Tony Cataldo | Chairman & Chief Executive Officer |
Martin Schroeder | Chief Technology Officer |
Greg Berk | Chief Medical Officer |
Justin Walsh | B. Riley Securities |
Ram Selvaraju | H.C. Wainwright |
Tony Butler | ROTH Capital |
Greetings and welcome to the GT Biopharma Second Quarter 2021 Conference Call. All participants are currently in a listen-only mode.
Following the formal presentation, we'll open the call up for a question-and-answer session. At this time, I'd like to turn the conference call over to David Castaneda, Investor Relations for the company. Thank you.